Austin G Kulasekararaj

List of Publications by Citations

149 papers	3,287 citations	29 h-index	56 g-index
160 ext. papers	4,384 ext. citations	4.6 avg, IF	5.02 L-index

#	Paper	IF	Citations
149	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. *Journal of Clinical Oncology*, **2011**, 29, 1971-9	2.2	342
148	Guidelines for the diagnosis and management of adult aplastic anaemia. *British Journal of Haematology*, **2016**, 172, 187-207	4.5	319
147	TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. *British Journal of Haematology*, **2013**, 160, 660-72	4.5	188
146	Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. *Blood*, **2011**, 117, 4552-60	2.2	167
145	Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. *Blood*, **2014**, 124, 2698-704	2.2	162
144	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*, **2019**, 133, 540-549	2.2	139
143	Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. *British Journal of Haematology*, **2015**, 171, 585-94	4.5	108
142	Functional characterization of CD4+ T cells in aplastic anemia. *Blood*, **2012**, 119, 2033-43	2.2	103
141	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. *Lancet Haematology,the*, **2017**, 4, e127-e136	14.6	95
140	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). *Haematologica*, **2014**, 99, 1041-9	6.6	95
139	Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1711-6	4.7	93
138	Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. *Blood*, **2016**, 128, 1193-205	2.2	76
137	Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. *British Journal of Haematology*, **2015**, 169, 565-73	4.5	74
136	Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. *Cell Reports*, **2017**, 20, 572-585	10.6	72
135	Autoimmune diseases and myelodysplastic syndromes. *American Journal of Hematology*, **2016**, 91, E280-3	7.1	69
134	Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. *OncoImmunology*, **2016**, 5, e1062208	7.2	62
133	Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. *Frontiers in Immunology*, **2019**, 10, 1157	8.4	62

132	Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. *British Journal of Haematology*, **2020**, 190, e279-e282	4.5	60
131	Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 562-8	4.7	56
130	Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*, **2014**, 99, 1574-81	6.6	54
129	SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. *Nature Communications*, **2015**, 6, 10004	17.4	51
128	Management of the refractory aplastic anemia patient: what are the options?. *Blood*, **2013**, 122, 3561-7	2.2	46
127	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. *Blood Advances*, **2018**, 2, 2176-2185	7.8	45
126	Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. *Oncotarget*, **2016**, 7, 22103-15	3.3	35
125	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. *Leukemia*, **2019**, 33, 2495-2505	10.7	34
124	Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. *British Journal of Haematology*, **2013**, 162, 587-605	4.5	34
123	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. *Haematologica* , **2021**, 106, 230-237	6.6	32
122	Terminal complement inhibition dampens the inflammation during COVID-19. *British Journal of Haematology*, **2020**, 190, e141-e143	4.5	29
121	Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. *Lancet Haematology,the*, **2019**, 6, e276-e284	14.6	29
120	Chronic relapsing remitting Sweet syndrome--a harbinger of myelodysplastic syndrome. *British Journal of Haematology*, **2015**, 170, 649-56	4.5	28
119	Heterozygous variants in bone marrow failure and myeloid neoplasms. *Blood Advances*, **2018**, 2, 36-48	7.8	27
118	Secondary HLH is uncommon in severe COVID-19. *British Journal of Haematology*, **2020**, 190, e283-e285	4.5	26
117	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). *Journal of Hematology and Oncology*, **2021**, 14, 168	22.4	24
116	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. *Haematologica*, **2016**, 101, 884-90	6.6	23
115	Human Erythroid Progenitors Are Directly Infected by SARS-CoV-2: Implications for Emerging Erythropoiesis in Severe COVID-19 Patients. *Stem Cell Reports*, **2021**, 16, 428-436	8	23

114	Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. *Haematologica*, **2021**, 106, 3188-3197	6.6	21
113	Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. *Leukemia*, **2021**, 35, 3223-3231	10.7	18
112	Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. *Nature Cell Biology*, **2020**, 22, 526-533	23.4	16
111	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. *British Journal of Haematology*, **2020**, 191, 476-485	4.5	15
110	RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis. *Oncotarget*, **2016**, 7, 47875-47890	3.3	15
109	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. *Seminars in Hematology*, **2019**, 56, 262-278	4	14
108	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. *Haematologica*, **2020**, 105, 1223-1231	6.6	14
107	Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis. *Acta Haematologica*, **2016**, 136, 23-42	2.7	14
106	CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. *Lancet Haematology,the*, **2015**, 2, e212-21	14.6	13
105	Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. *American Journal of Hematology*, **2018**, 93, E88-E91	7.1	13
104	Myelodysplastic syndrome can propagate from the multipotent progenitor compartment. *Haematologica*, **2017**, 102, e7-e10	6.6	12
103	Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag. *Haematologica*, **2019**, 104, e494-e496	6.6	12
102	Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK. *Blood*, **2012**, 120, 3472-3472	2.2	12
101	A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy. *Blood*, **2019**, 134, 3514-3514	2.2	10
100	Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. *American Journal of Hematology*, **2016**, 91, E16-7	7.1	10
99	One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. *Therapeutic Advances in Hematology*, **2020**, 11, 2040620720966137	5.7	9
98	Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients. *Blood*, **2010**, 116, 125-125	2.2	8
97	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. *PLoS ONE*, **2020**, 15, e0237497	3.7	8

96	Tissue Iron Distribution Assessed by MRI in Patients with Iron Loading Anemias. *PLoS ONE*, **2015**, 10, e0139220	3.7	7
95	One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. *European Journal of Haematology*, **2021**, 106, 389-397	3.8	7
94	Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. *Bone Marrow Transplantation*, **2021**, 56, 2600-2602	4.4	7
93	Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. *Blood*, **2021**, 138, 1928-1938	2.2	7
92	Natural Killer Cell Lymphoblastic Leukaemia/Lymphoma: Case Report and Review of the Recent Literature. *Case Reports in Oncology*, **2017**, 10, 588-595	1	6
91	Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis. *Clinical Infectious Diseases*, **2019**, 69, 1757-1763	11.6	6
90	Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. *Expert Opinion on Biological Therapy*, **2020**, 20, 227-237	5.4	6
89	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. *Leukemia*, **2020**, 34, 2441-2450	10.7	6
88	Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.. *Frontiers in Immunology*, **2021**, 12, 791429	8.4	6
87	Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients. *Frontiers in Immunology*, **2020**, 11, 1006	8.4	5
86	Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome. *Blood*, **2014**, 124, 3269-3269	2.2	5
85	Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. *British Journal of Cancer*, **2021**, 125, 939-947	8.7	5
84	Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum. *British Journal of Haematology*, **2020**, 190, e248-e250	4.5	4
83	Somatic Mutations Implicated In Myeloid Malignancies Are Frequent In Idiopathic Aplastic Anaemia and Its Relevance To Disease Classification and Treatment- a Comprehensive Analysis Of 150 Patients. *Blood*, **2013**, 122, 803-803	2.2	4
82	Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. *British Journal of Haematology*, **2021**,	4.5	4
81	Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. *BioDrugs*, **2020**, 34, 149-158	7.9	4
80	Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. *American Journal of Hematology*, **2021**, 96, E232-E235	7.1	4
79	British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. *British Journal of Haematology*, **2021**, 194, 282-293	4.5	4

78	British Society for Haematology guidelines for the management of adult myelodysplastic syndromes. *British Journal of Haematology*, **2021**, 194, 267-281	4.5	4
77	Sideroblastic anemia with myopathy secondary to novel, pathogenic missense variants in the gene. *Haematologica*, **2018**, 103, e564-e566	6.6	4
76	Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19.. *JAMA Network Open*, **2022**, 5, e220130	10.4	4
75	Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases. *Blood*, **2013**, 122, 746-746	2.2	3
74	COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP. *Blood Advances*, **2021**,	7.8	3
73	SARS-CoV-2 infection in aplastic anaemia. *Haematologica*, **2021**,	6.6	3
72	Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis. *European Journal of Haematology*, **2021**, 107, 3-23	3.8	3
71	Erdheim-Chester Disease: Case Report with Aggressive Multisystem Manifestations and Review of the Literature. *Case Reports in Oncology*, **2017**, 10, 501-507	1	2
70	Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016: Experience from four leading tertiary care hematopoietic stem cell transplantation centers. *Hematology/ Oncology and Stem Cell Therapy*, **2021**, 14, 169-178	2.7	2
69	Coombs-positive Paroxysmal Nocturnal Haemoglobinuria. *Oxford Medical Case Reports*, **2020**, 2020, omz125	0.5	2
68	Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. *European Journal of Haematology*, **2018**, 101, 466-474	3.8	2
67	Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. *British Journal of Haematology*, **2019**, 187, e20-e24	4.5	2
66	Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience. *Frontiers in Oncology*, **2019**, 9, 623	5.3	2
65	The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q. *PharmacoEconomics - Open*, **2019**, 3, 351-358	2.1	2
64	Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria.. *European Journal of Haematology*, **2022**,	3.8	2
63	Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). *Blood*, **2021**, 138, 2196-2196	2.2	2
62	Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry. *European Journal of Haematology*, **2020**, 105, 561-570	3.8	2
61	Romiplostim in aplastic anaemia - another tool in the armamentarium. *British Journal of Haematology*, **2021**, 192, 15-16	4.5	2

60	Early and late-onset veno-occlusive disease/sinusoidal syndrome post allogeneic stem cell transplantation - a real-world UK experience. *American Journal of Transplantation*, **2021**, 21, 864-869	8.7	2
59	Clonal dominance of PNH- another piece to the jigsaw. *British Journal of Haematology*, **2017**, 177, 9-10	4.5	1
58	Sweet spot for cyclophosphamide: a balancing act. *Lancet Haematology,the*, **2015**, 2, e350-1	14.6	1
57	Regulatory cells in immune-mediated aplastic anaemia - not T but B. *British Journal of Haematology*, **2020**, 190, 486-487	4.5	1
56	British Committee for Standards in Haematology guidelines for aplastic anemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of 20□□10 /L - RESPONSE to Yan et□al. *British Journal of Haematology*, **2018**, 182, 286-287	4.5	1
55	De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow Necrosis without Adenopathy or Organomegaly. *Case Reports in Hematology*, **2015**, 2015, 146598	0.7	1
54	The non-transplant treatment of myelodysplastic syndromes-what's on the horizon?. *Seminars in Hematology*, **2012**, 49, 350-60	4	1
53	Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks. *Blood*, **2020**, 136, 37-38	2.2	1
52	Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors. *Blood*, **2020**, 136, 43-44	2.2	1
51	Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients. *Blood*, **2019**, 134, 4797-4797	2.2	1
50	BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). *Blood*, **2020**, 136, 14-15	2.2	1
49	Low Level Residual Extravascular Haemolysis Is Commom Following Eculizumab Treatment In Paroxysmal Nocturnal Haemoglobinuria(PNH), but Does Not Affect Transfusion Requirement. *Blood*, **2010**, 116, 4240-4240	2.2	1
48	Whole Exome Sequencing Reveals Acquired SF3B1 Mutations Defining Patients with Acquired Idiopathic Sideroblastic Anaemia. *Blood*, **2011**, 118, 2793-2793	2.2	1
47	Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency,. *Blood*, **2011**, 118, 3826-3826	2.2	1
46	5-Azacytidine Specifically Depletes Regulatory T Cells (Tregs) in Myelodysplastic Syndrome (MDS) Patients. *Blood*, **2011**, 118, 787-787	2.2	1
45	TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis. *Blood*, **2011**, 118, 792-792	2.2	1
44	Feasibility and Optimal Schedule Of Using Eculizumab In Patients With Hemolytic Paroxysmal Nocturnal Hemoglobinuria (hPNH) With Severe Aplastic Anemia (SAA) Prior To Haemopoietic Stem Cell Transplant (HSCT). *Blood*, **2013**, 122, 2482-2482	2.2	1
43	Comparison of Peripheral Blood and Bone Marrow Molecular Profiling in Primary Myelodysplastic Syndromes (MDS). *Blood*, **2014**, 124, 4655-4655	2.2	1

42	Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort. *Blood*, **2019**, 134, 4566-4566	2.2	1
41	Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.. *Blood*, **2009** , 114, 733-733	2.2	1
40	Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy. *Blood*, **2013** , 122, 2792-2792	2.2	1
39	Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy-Is it prognostic?-a single-center retrospective study. *Blood Cancer Journal*, **2021**, 11, 128	7	1
38	The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. *Therapeutic Advances in Hematology*, **2022**, 13, 204062072210910	5.7	1
37	Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for Blood and Marrow Transplantation (SAAWP of EBMT). *Bone Marrow Transplantation*, **2021**, 56, 2518-2532	4.4	0
36	Upfront unrelated donor hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: A retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation. *American Journal of Hematology*, **2021**,	7.1	0
35	Acquired Aplastic Anaemia and Paroxysmal Nocturnal Haemoglobinuria **2015**, 174-194		
34	Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension. *Blood*, **2020**, 136, 31-33	2.2	
33	Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors. *Blood*, **2020**, 136, 34-34	2.2	
32	Association between Transfusion Status (TS) and Clinical and Economic Outcomes in Patients with Myelodysplastic Syndromes (MDS) from the Physicians' Perspective. *Blood*, **2020**, 136, 28-29	2.2	
31	Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies. *Blood*, **2020**, 136, 42-43	2.2	
30	Physicians' Experience in Blood Supply Shortages and the Top Factors That Impact the Clinical, Economic, and Humanistic Outcomes of Myelodysplastic Syndrome (MDS) Patients in 5 European Countries. *Blood*, **2020**, 136, 43-44	2.2	
29	Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy. *Blood*, **2021**, 138, 4313-4313	2.2	
28	The Outcome of Lymphoproliferative Disorder in Liver Transplant Recipients May Correlate with Age at Diagnosis and the Use of Chemotherapy: A Single Centre Report.. *Blood*, **2005**, 106, 1435-1435	2.2	
27	Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab. *Blood*, **2018**, 132, 625-625	2.2	
26	Understanding the Association between Transfusion Status (TS) and Overall Survival (OS), and Other Clinical Outcomes in Patients with Myelodysplastic Syndromes (MDS) from the Physicians' Perspective: A Pilot Survey. *Blood*, **2019**, 134, 5901-5901	2.2	
25	Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations. *Blood*, **2019**, 134, 3749-3749	2.2	

24	Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience. *Blood*, **2019**, 134, 4622-4622	2.2
23	A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes. *Blood*, **2019**, 134, 5838-5838	2.2
22	Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity. *Blood*, **2014**, 124, 1236-1236	2.2
21	Telomere Gene Complex Mutations Are Frequently Found with Shortened Telomeres in Bone Marrow Failure Syndromes and Idiopathic Pulmonary Fibrosis; Correlation with Haematological and Clinical Features. *Blood*, **2014**, 124, 2935-2935	2.2
20	Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7. *Blood*, **2014**, 124, 4662-4662	2.2
19	Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy. *Blood*, **2015**, 126, 2839-2839	2.2
18	Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab: A UK Experience. *Blood*, **2016**, 128, 2683-2683	2.2
17	Comparative Analysis of Sibling Donor Reduced Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte Globulin Versus Alemtuzumab for T-Cell Depletion.. *Blood*, **2009**, 114, 3362-3362	2.2
16	Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Disease.. *Blood*, **2009**, 114, 2560-2560	2.2
15	Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype. *Blood*, **2010**, 116, 2729-2729	2.2
14	Reduction of Tregs with Expansion of Th1 Cells and Lack of IFN-γ Secretion by GPI Negative T-Cells In PNH. *Blood*, **2010**, 116, 2240-2240	2.2
13	A Functional Assay for MicroRNA Target Identification and Validation. *Blood*, **2010**, 116, 3874-3874	2.2
12	The JAK2 46/1 Haplotype Analysis In Essential Thrombocythaemia and Polycythaemia Rubra Vera Reveals That CC Genotype Is Associated with a Higher JAK2V617F and c-MPL W515 Allele Burden. *Blood*, **2010**, 116, 1977-1977	2.2
11	Microsatellite Instability (MSI) In High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Cells Promotes Frameshift Mutations In DNA Repair Genes: Indications for PARP Inhibitor Therapy.. *Blood*, **2010**, 116, 1194-1194	2.2
10	Single Nucleotide Polymorphism Array (SNP-A) Karyotype Is the Best Predictor of Prognosis In Normal Cytogenetics Acute Myeloid Leukaemia (AML). *Blood*, **2011**, 118, 411-411	2.2
9	Microsatellite Instability Induced Mutation in DNA Repair Genes, CTiP and Mre11 Confer Hypersensitivity to PARP Inhibitors in Myeloid Malignancies. *Blood*, **2011**, 118, 276-276	2.2
8	Pre-Emptive Donor Lymphocyte Infusions (DLI) Lead to High Cure Rates in T-Cell Depleted Allogeneic Haemopoietic Stem Cell Transplants for MDS/AML. *Blood*, **2011**, 118, 660-660	2.2
7	STAT3-Mutations Indicate the Presence of Subclinical Self-Reactive Cytotoxic T Cell Clones in Aplastic Anemia and Myelodysplastic Syndromes. *Blood*, **2012**, 120, 646-646	2.2

6	Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML.. *Blood*, **2012**, 120, 3141-3141	2.2
5	Chronic Relapsing Remitting Sweet Syndrome- a Harbinger Of Myelodysplastic Syndrome (MDS), Single Centre Analysis Of 31 Patients. *Blood*, **2013**, 122, 2793-2793	2.2
4	Characteristics and Outcome Of Acute Myeloid Leukemia Following Breast Cancer: Analysis Of 408 Cases and Controls. *Blood*, **2013**, 122, 1408-1408	2.2
3	SF3B1 Mutant Clones From Patients With Refractory Anaemia With Ringed Sideroblasts (RARS) Originate From The Early Haematopoietic Stem Cells and Maintain Their Engraftment Potential. *Blood*, **2013**, 122, 262-262	2.2
2	Myeloid Derived Suppressor Cell Expansion Correlates With Increased regulatory T Cells In Myelodysplastic Syndrome. *Blood*, **2013**, 122, 2766-2766	2.2
1	Limited utility of the HScore in detecting secondary haemophagocytic lymphohistiocytosis in COVID-19: response. *British Journal of Haematology*, **2021**, 194, 688-689	4.5